Open AccessManaging Lung Cancer during Coronavirus Disease 2019 Pandemic
Author(s) -
Yara Khalifeh,
Arafat Tfayli
Publication year - 2021
Publication title -
turkish thoracic journal
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.257
H-Index - 7
ISSN - 2149-2530
DOI - 10.5152/turkthoracj.2021.20110
Subject(s) - pandemic , lung cancer , medicine , intensive care medicine , disease , covid-19 , cancer , coronavirus , infectious disease (medical specialty)
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as a pandemic by the World Health Organization. As this disease continues to spread worldwide, it has posed enormous challenges on the healthcare of several diseases, especially cancer, because hospital facilities have invested health resources for patients with COVID-19. Indeed, patients with lung cancer are particularly vulnerable because of their poor baseline lung function and cancer-related treatment. In addition, once infected, they are at an increased risk of pulmonary complications from COVID-19. Oncologists are thus facing a challenge as how to balance the treatment plans to control the disease while protecting the patients with lung cancer from COVID-19. In fact, it is crucial to provide individualized treatment recommendations to limit the risks during these difficult times. This review highlights the key challenges that oncologists face when diagnosing COVID-19 among patients with lung cancer and examines the current recommendations from available literature, clinical expertise, and expert opinions regarding managing lung cancer in the era of COVID-19. It also explores the treatment approach recommended for patients with lung cancer while avoiding putting them at excessive risk of contracting COVID-19 infection.